Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics
Article content
– Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder ('MDD') with expected combined enrollment of approximately 550 participants across three studies (APPROACH™, EMBRACE™, and EXTEND) –
Article content
Article content
– Partnerships with Osmind and Thermo Fisher Scientific strengthen the Company's commercialization and manufacturing capabilities –
Article content
– Positive regulatory signals from U.S. Agencies amid expanding media coverage could expedite regulatory pathways across Cybin's clinical-stage pipeline –
Article content
TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update.
Article content
'It is especially gratifying that at a time when we are advancing our clinical pipeline programs, with our lead program CYB003 in Phase 3 development, the path toward approval and eventual commercialization of psychedelic therapeutics is gaining clarity,' said Doug Drysdale, Chief Executive Officer of Cybin. 'With our expanded intellectual property portfolio, and a number of key partnerships in place, we believe our rigorous research and novel clinical approach can lead to a transformation in how mental health disorders are treated. Now is the time to address the mental health crisis, and we are encouraged by recent sentiment in favor of expediting the regulatory review process for product candidates in development.'
Article content
Continued to expand its strategic clinical site partnership ('SPA') program in support of the Phase 3 PARADIGM program. The SPA program is designed to facilitate collaboration among sites, enhance efficiency in trial operations, and improve overall site performance.
Partnered with Thermo Fisher Scientific, a world-class manufacturing partner, to provide U.S.-based manufacturing for the CYB003 program. Cybin broadened its existing strong relationship with Thermo Fisher Scientific to include the development of both the drug substance and drug product capsules for CYB003.
Partnered with Osmind, a leading service provider to psychiatry practices in the U.S., with the objective of accelerating commercial preparation for clinical-stage pipeline. Osmind advances psychiatry through technology and services to bring innovative mental health treatments to patients in need. Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support commercial preparation for its clinical-stage pipeline.
Continued to expand intellectual property portfolio with two additional U.S. patents supporting lead programs CYB003 and CYB004, bringing the total to over 90 granted patents and over 230 pending applications. The recently issued patents are as follows:
U.S. patent 12,291,499 includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041.
U.S. patent 12,318,477 is expected to provide exclusivity until 2040 and includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular ('IM') injection, including CYB004.
Article content
Positive Regulatory Signals and Evolving Acceptance of Potential Therapeutic Value of Psychedelics
Article content
Recent statements and hiring decisions by senior U.S. Health and Human Services ('HHS') and FDA officials, in addition to ongoing signs of bipartisan congressional support, suggest an improved forward regulatory environment for psychedelic medicine and therapies, including the potential for accelerated approval pathways.
Article content
The Company believes that these developments, together with increased political recognition and public understanding of the science underpinning these programs, have the potential to expedite regulatory pathways and reduce overall risk across its clinical portfolio. Highlights include:
Article content
In a recent interview, FDA Commissioner Dr. Marty Makary stated that psychedelic-drug review is a 'top priority' and promised an 'expeditious and rapid review' of clinical data. 1
Article content
Drug-policy lawyer, Matthew Zorn, has joined HHS as Deputy General Counsel to work on psychedelics policy. He previously challenged the government on matters such as allowing research on cannabis for veterans with PTSD, preventing tryptamines from being scheduled, and fighting for patient access to psilocybin under Right to Try laws. 2
Article content
Navy-SEAL-turned-Congressman Morgan Luttrell recently urged the GOP to 'embrace' compounds such as psilocybin, MDMA and ibogaine to help veterans with PTSD. 3
Article content
President Trump's new pick for surgeon general, Dr. Casey Means, wrote in a recent book that people should consider guided-psychedelic therapy. 4
Article content
On June 19, 2025, Doug Drysdale will speak in a panel discussion focused on the regulatory landscape and next steps for potential commercialization, at the Psychedelic Science 2025 Conference taking place June 16-20, 2025, in Denver, Colorado. The panel details are as follows:
Article content
Panel Title:
Article content
Date and Time:
Article content
About Cybin
Article content
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
Article content
With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Article content
Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.
Sources
Article content
NewsNation, 'FDA Commissioner Says Research on Psychedelic Treatment 'Top Priority',' interview with FDA Commissioner Dr. Marty Makary, video posted May 16, 2025, https://www.youtube.com/watch?v=KEQFKBME668 (accessed June 9, 2025).
Politico, 'A Psychedelics Hire at HHS,' newsletter article, published May 28 2025, https://www.politico.com/newsletters/future-pulse/2025/05/28/a-psychedelics-hire-at-hhs-00371416 (accessed June 9 2025).
The Wall Street Journal, 'Lawmaker 'Reborn' Through Psychedelic Therapy Wants the GOP to Embrace It,' news article, published May 17 2025, https://www.wsj.com/politics/policy/republican-psychedelic-drug-therapy-fc313ea2 (accessed June 9 2025).
The Associated Press, 'Trump Surgeon General Pick Praised Unproven Psychedelic Therapy, Said Mushrooms Helped Her Find Love,' news article, published May 14 2025, https://apnews.com/article/means-trump-surgeon-general-mushrooms-psychedelic-drugs-72c22ed077409b4bb865214e7ef304a8 (accessed June 9 2025).
Fox News. 'Trump Administration Exploring Potential Benefits of Psychedelic Treatments.' America's Newsroom, correspondent Alexandria Hoff, broadcast June 5 2025. Video clip, 1:58. https://www.foxnews.com/video/6373914669112
Article content
Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to enroll participants and add additional clinical sites for the PARADIGM program; regulatory statements that suggest an expedited regulatory pathway for Cybin programs; the anticipated approval and commercialization of CYB003 and CYB004; the ability to accelerate commercial preparation of clinical-stage programs through the Company's partnership with Osmind; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.
Article content
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Article content
Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Investor & Media:
Article content
Article content
Gabriel Fahel
Article content
Article content
Chief Legal Officer
Article content
Article content
Cybin Inc.
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
33 minutes ago
- Globe and Mail
Canaccord Genuity Keeps Their Buy Rating on Tesla (TSLA)
Canaccord Genuity analyst George Gianarikas reiterated a Buy rating on Tesla yesterday and set a price target of $303.00. The company's shares closed yesterday at $315.65. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Gianarikas covers the Industrials sector, focusing on stocks such as Surf Air Mobility, Inc., NuScale Power, and Arq Inc. According to TipRanks, Gianarikas has an average return of 1.2% and a 42.64% success rate on recommended stocks. The word on The Street in general, suggests a Hold analyst consensus rating for Tesla with a $285.73 average price target, implying a -9.48% downside from current levels. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $307.00 price target. The company has a one-year high of $488.54 and a one-year low of $182.00. Currently, Tesla has an average volume of 120.5M. Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is neutral on the stock. Last month, Xiaotong Zhu, the SVP, APAC of TSLA sold 15,000.00 shares for a total of $4,857,000.00.
CBC
an hour ago
- CBC
Automakers want Canada to scrap its EV sales mandate. What would that do to emissions?
Automakers push Ottawa to drop EV mandates 1 day ago Duration 1:57 Social Sharing When Prime Minister Mark Carney met with automotive sector CEOs Wednesday about U.S. trade negotiations, one of the key issues the industry said they wished to discuss was the government's zero-emission vehicle (ZEV) mandate. The mandate requires a certain percentage of light duty vehicles — passenger cars, SUVs and trucks — that are sold to be either fully-electric vehicles or plug-in hybrids, starting with 20 per cent in 2026 and rising to 100 per cent by 2035. Brian Kingston, president and CEO of the Canadian Vehicle Manufacturers' Association, told CBC News on the way to the meeting that "The targets that have been established cannot be met" given current market forces. He later added that Canada already has other policies to meet its greenhouse gas emission targets. Burning fossil fuels such as gasoline and diesel is the main cause of climate change, and transportation is the second-biggest source of emissions in Canada after the oil and gas industry. The ZEV mandate is part of Canada's strategy to accelerate the adoption of electric vehicles and decarbonize the transportation sector. But if the mandate were scrapped, analysts say that would hurt efforts to fight climate change — and make it harder to find an EV for sale in parts of the country. Here's a closer look at why. How big a deal are emissions from passenger vehicles? In 2023, transportation accounted for 23 per cent of Canada's greenhouse gas emissions. Unlike some sectors that have cut emissions since 1990, transportation emissions have grown 33 per cent, driven by both freight heavy-duty trucks and passenger light trucks. Passenger vehicles alone accounted for about 12 per cent of Canada's emissions in 2023. The Canadian Climate Institute, a climate policy think-tank partly funded by Environment and Climate Change Canada, modelled 60 potential net-zero scenarios and found that switching to zero-emission vehicles was central to every one. Arthur Zhang, senior research associate at the institute, said EVs are "one of the most reliable technologies we have for reducing emissions in the transportation sector." WATCH | Canada's plan to phase out gas-powered cars and trucks Canada's plan to phase out gas-powered car and truck sales by 2035 2 years ago Duration 2:04 How would the ZEV mandate increase EV adoption? It aims to solve a few problems. One of the challenges up until now has been the lack of availability of electric vehicles in many parts of Canada. In a recent interview, Cara Clairman, president and CEO of Plug'n Drive, an organization focused on public education about EVs, said in many parts of Canada, it's still impossible to find an EV to test drive, due to low availability at dealerships. The exceptions are B.C. and Quebec, which have their own ZEV sales mandates. "That means more dealers have [electric] cars," she said. "If the vehicles are on the lots, you know, they sell more EVs. That's just the reality." Zhang said the mandate signals government support for the EV transition and gives manufacturers the push to focus on electric vehicles even during periods of slower demand, such as now. EVs accounted for 7.53 per cent of all new vehicles sold in April, down from a peak of 18.29 per cent in December 2024, now that federal, Quebec and B.C. rebates are gone. The federal government says a new rebate program is in the works, which consumers are waiting for, and Kingston says that's hurting EV sales right now. Electric vehicles are becoming easier to find in Canada, but not easier to afford 1 year ago Duration 1:54 Electric vehicles are becoming easier to find at Canadian auto dealers, but they are still more expensive than most gas-powered vehicles. EV experts encourage drivers to consider fuel savings and provincial incentives as they mull over their next car purchase. And he said it could also potentially lower the price of EVs, as manufacturers and importers boost the price of gas-burning vehicles relative to EVs and "cross-subsidize" them in order to meet sales targets. Ross McKitrick, an economics professor at the University of Guelph and an unpaid senior fellow at the Fraser Institute, predicted such a markup of gas vehicles in a recent study modelling the economic impacts of the ZEV mandate. However, he found that the extra markup from gas-burning vehicles would be offset by lower overall sales due to higher vehicle prices overall (reducing the size of Canada's vehicle fleet by 0.6 per cent by 2050). Manufacturers or importers can also earn credits toward the target by selling more EVs ahead of time, overshooting the target some years, or installing EV charging infrastructure, which could also help boost demand for EVs. However, those who don't meet the targets even with the credits would face penalties. Road to EV adoption: Why experts think the future is still electric 10 months ago Duration 5:47 Recent headlines have suggested that consumers are losing interest in electric vehicles, but a closer look at the trends tells a different story. CBC's Nisha Patel breaks down where we're at in the EV transition and why experts say the future is still electric. What impact would the mandate have on emissions? McKitrick's study found that initially, the impact would be modest, as people's cars age slowly before needing replacement. But by 2050, the EV mandate will have cut Canada's greenhouse gas emissions by roughly eight per cent compared to a "base scenario" without an EV mandate. That's large, considering that passenger vehicles make up 12 per cent of emissions right now, and emissions would already be declining due to some adoption of EVs. McKitrick said scrapping the mandate would mean forgoing that eight per cent cut to emissions. Couldn't other policies cut emissions if the ZEV mandate gets scrapped? Zhang said government subsidies such as funding for EV charging infrastructure and rebates for people buying EVs can make a difference, but those work better as complementary policies: "They are not substitutes to the mandate as far as emissions reductions go," he said. He added that subsidies rely on taxpayer dollars, which may be less efficient than a policy to encourage manufacturers to make EVs more attractive. On the other hand, McKitrick calculated that the ZEV mandate would be roughly 10 times more expensive per tonne of carbon abated than the former federal carbon tax, which Prime Minister Mark Carney eliminated in March – although the ZEV mandate's "cost" would fall to zero once EVs and gas cars cost the same. That's already the case in some places outside Canada, Zhang said. WATCH | The North American fight against cheap Chinese EVs, explained The North American fight against cheap Chinese EVs, explained | About That 10 months ago Duration 9:04 Canada is stepping in line with the U.S. and imposing 100 per cent tariffs on all electric vehicles coming from China to combat the "unfair advantage" it has in the global marketplace. About That producer Lauren Bird explores why North America is closing the door on a massive source of cheap electric vehicles and why experts say consumers will pay the price. CORRECTION: At 1:47 in this video, we state that the cheapest Tesla on the market as of Aug. 28, 2024, in the U.S. is a Model Y for about $45,000 USD. In fact, the cheapest Tesla you can buy in the U.S. without a federal tax credit is the Model 3 Rear-Wheel Drive for $38,990. One strategy to boost EV sales and adoption that has been proposed by academics and EV advocates has been to scrap tariffs on Chinese cars, which sell for as little as $13,000 Cdn overseas. Zhang acknowledged, "In the case where cheaper EVs are available to consumers, the EV mandate may not be as impactful."
CBC
an hour ago
- CBC
Ontario wine sales surge after U.S. products pulled
Sales of Ontario wine have increased by over 60 per cent since the LCBO pulled American products off its shelves earlier this year, signalling a shift in buying habits among consumers in the province, the retailer says. "Ontarians are increasingly committed to buying local and Canadian products," an LCBO spokesperson said in a statement. "VQA wine (made from 100% Ontario-grown grapes) has seen a sales increase of over 60%, with VQA reds and whites seeing growth of 71% and 67% respectively, and VQA sparkling wine growing by +28%." From the beginning of March until early June, total wine sales dropped by 13 per cent, the LCBO added. In response to U.S. tariffs, the Ontario government directed the LCBO in March to implement restrictions on all U.S. beverage alcohol sales and related imports. Spirits, wine, cider, beer, ready-to-drink coolers/cocktails and non-alcoholic drinks produced in the U.S. were promptly pulled from the shelves of LCBO retail stores and convenience outlets. The move has been an "opportunity" for local wine makers, according to Del Rollo, former chair and current board member of Wine Growers Ontario. Rollo said Canadians have never been more passionate about supporting local and buying Canadian. "We're capitalizing on that as an industry and making sure that the shelves are full, and they're tasting the wines and they're loving them," Rollo said. Restaurants, wineries also seeing boost The shift toward sipping Ontario wine has also given a boost to local restaurants and wineries. At Kin Vineyards in Carp, sales have increase by about 25 per cent since the trade war began, according to retail manager Liam Mastersmith. Mastersmith's family owns the vineyard that he says is home to the northernmost Pinot Noir and Chardonnay grapes in the province. The company sells most of its wine at the vineyard and through restaurants, and it's also available in select LCBO stores. "The Ottawa Valley has always been great at supporting local anyway, and so what we've seen is that more people from outside of the Ottawa Valley are coming in and trying our wines," Mastersmith said. Customer William Hordyk grew up near Ontario's renowned Niagara wine region and says supporting local producers has always been important, but now he's paying even more attention. "I'm more conscious about it now and definitely looking more closely at it to make sure I'm supporting the local Canadian and Ontario wineries," he said. Ontario wine sales also seem to have legs in local restaurants. Stephen Beckta, owner of Beckta Dining & Wine, Gezellig and Play Food & Wine in Ottawa, got a lot of attention when he publicly announced the removal of all American wines from his menus earlier this year. Since then, he said sales of Ontario wines in his restaurants have jumped about 30 per cent. Beckta said he wants the trade war to end, but customers have been very receptive to trying new Canadian and Ontario wines. "What we've seen is a greater confidence about supporting our own industries, and that is the wonderful byproduct that will be here regardless of when the trade war actually ends," he said. The LCBO said in addition to VQA wine, other Ontario-made wine categories such as international-domestic blends are experiencing modest growth, while Canadian wine has experienced strong growth in response to demand, up about 18 per cent.
